Protagenic TherapeuticsPTIX
13F holders, Q1 2026 (March 31)4holders −8
1new positions
9sold out
$0.66avg. 13F price*
At the end of Q1 2026, 4 institutions reported holding Protagenic Therapeutics Inc. (PTIX) in their 13F filings, down 8 from Q4 2025. 1 opened new positions and 9 sold out. The largest holders were DRW Securities, LLC ($28K), FNY Investment Advisers, LLC ($16K) and CoreCap Advisors, LLC ($68).
- Company
- Protagenic Therapeutics Inc.
- CUSIP
- 74365N301
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q4 2025 → Q1 2026
| Institutions | Total Value | |
|---|---|---|
| New Positions | 1 | $68 |
| Exits | 9 | $63K |
All 13F filers, Q4 2025 → Q1 2026: 100 shares bought and 49,680 shares sold, net −49,580 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 4 holders
| DRW Securities, LLC | 0.00% | Reduce -2.5% | 41,783 | $28K |
| FNY Investment Advisers, LLC | 0.01% | No change | 25,000 | $16K |
| CoreCap Advisors, LLC | 0.00% | New | 100 | $68 |
| United Financial Planning Group LLC | 0.00% | No change | 17 | $12 |
"% of holder's portfolio" is PTIX's weight in each manager's 13F, not the share of Protagenic Therapeutics Inc. the manager owns.